Free Trial

CME Group (CME) Stock Forecast & Price Target

CME Group logo
$265.92 +2.33 (+0.88%)
As of 03:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CME Group - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
2
Hold
6
Buy
6

Based on 14 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Hold." Out of the 14 analysts, 2 have given a sell rating, 6 have given a hold rating, and 6 have given a buy rating for CME.

Consensus Price Target

$275.17
3.48% Upside
According to the 14 analysts' twelve-month price targets for CME Group, the average price target is $275.17. The highest price target for CME is $312.00, while the lowest price target for CME is $219.00. The average price target represents a forecasted upside of 3.48% from the current price of $265.93.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CME Analyst Ratings Over Time

TypeCurrent Forecast
10/8/24 to 10/8/25
1 Month Ago
9/8/24 to 9/8/25
3 Months Ago
7/10/24 to 7/10/25
1 Year Ago
10/9/23 to 10/8/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
Hold
6 Hold rating(s)
9 Hold rating(s)
8 Hold rating(s)
7 Hold rating(s)
Sell
2 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
4 Sell rating(s)
Consensus Price Target$275.17$260.60$260.93$217.71
Forecasted Upside3.48% Upside-0.75% Downside-5.18% Downside-1.79% Downside
Consensus RatingHoldHoldHoldReduce

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CME Group Stock vs. The Competition

TypeCME GroupFinance CompaniesS&P 500
Consensus Rating Score
2.29
2.30
2.51
Consensus RatingHoldHoldModerate Buy
Predicted Upside4.39% Upside120.51% Upside170.19% Upside
News Sentiment Rating
Positive News

See Recent CME News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/8/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingBuy (B)
10/1/2025Morgan Stanley
3 of 5 stars
Patrick Moley
Not Rated
Boost TargetOverweight$303.00 ➝ $312.00+17.37%
9/25/2025JPMorgan Chase & Co.
2 of 5 stars
Boost TargetUnderweight$246.00 ➝ $252.00-4.70%
9/25/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$275.00 ➝ $300.00+13.45%
9/8/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$305.00 ➝ $285.00+8.80%
7/24/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$300.00 ➝ $303.00+9.30%
7/24/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set TargetEqual Weight$299.00 ➝ $298.00+7.78%
7/15/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$283.00 ➝ $296.00+8.10%
5/24/2025Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
4/24/2025Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetMarket Perform$265.00 ➝ $273.00+2.83%
4/3/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSector Perform$269.00 ➝ $269.00-0.64%
4/2/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetUnderperform$200.00 ➝ $219.00-16.64%
3/10/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$287.00+12.74%
11/11/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetHold$227.00 ➝ $226.00-0.14%
10/8/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral$244.00+10.04%
10/3/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetSell$195.00 ➝ $198.00-11.89%
9/26/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold$221.00+1.60%
4/25/2024Rosenblatt Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingSell$185.00 ➝ $187.00-12.04%
3/6/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$225.00 ➝ $245.00+12.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:16 PM ET.


Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 5, 2025. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CME Group Inc.:

  • The current stock price is around $271, which may present a buying opportunity for investors looking for value in the market.
  • CME Group Inc. has a solid dividend yield of approximately 1.8%, providing a steady income stream for investors through its annualized dividend of $5.00.
  • Recent analyst upgrades, including a "buy" rating from Citigroup and an increased price target, suggest positive sentiment and potential for stock appreciation.
  • The company has a relatively low dividend payout ratio of 48.40%, indicating that it retains a significant portion of its earnings for reinvestment, which could support future growth.
  • Insider transactions show confidence in the company, with recent sales by insiders indicating a strategic approach to their holdings rather than a lack of faith in the company's future.

CME Group
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CME Group Inc. for these reasons:

  • Insider sales have totaled over 13,000 shares in the last three months, which could signal a lack of confidence among company executives regarding future stock performance.
  • Analysts have mixed ratings on the stock, with several holding a "sell" or "underweight" rating, indicating potential concerns about the company's growth prospects.
  • The stock has experienced fluctuations, and the recent average price targets set by analysts vary significantly, suggesting uncertainty in the market's outlook for CME Group Inc.
  • Corporate insiders own only 0.30% of the company's stock, which may indicate a lack of alignment between management and shareholder interests.
  • Market conditions for trading futures and options can be volatile, which may impact CME Group Inc.'s revenue and profitability in the near term.

CME Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $275.17, with a high forecast of $312.00 and a low forecast of $219.00.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CME shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CME, but not buy additional shares or sell existing shares.

According to analysts, CME Group's stock has a predicted upside of 3.48% based on their 12-month stock forecasts.

Over the previous 90 days, CME Group's stock had 1 upgrade by analysts.

CME Group has been rated by research analysts at Barclays, Citigroup, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer, Piper Sandler, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like CME Group less than other "finance" companies. The consensus rating score for CME Group is 2.29 while the average consensus rating score for "finance" companies is 2.31. Learn more on how CME compares to other companies.


This page (NASDAQ:CME) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners